The ability to identify and evaluate the severity of tau pathology in the brain represents a critical component of Alzheimer's disease diagnosis and disease progression staging. This model proposes that tau pathology burden—assessed through Braak staging, PET imaging, and fluid biomarkers—provides crucial diagnostic and prognostic information, particularly after beta-amyloid deposition plateaus, and offers a powerful approach for evaluating anti-tau treatment efficacy [1][2].
The tau pathology assessment model integrates multiple modalities to create a comprehensive picture of neurodegeneration progression, enabling clinicians to:
The pathological accumulation of tau in Alzheimer's disease involves a cascade of molecular events:
The progressive spread of tau pathology follows patterns consistent with prion-like propagation:
| Mechanism | Description | Evidence |
|---|---|---|
| Trans-synaptic Transport | Tau seeds travel along axons to connected neurons | Animal models show anterograde spread [4] |
| Extracellular Vesicles | Tau released in exosomes propagates to neighbors | CSF exosome studies [@saman2012] |
| Direct Transfer | Cell-to-cell contact facilitates seed transfer | In vitro co-culture experiments |
| Template Seeding | Pathological tau converts normal tau | Strain studies in mice [@frost2009] |
Justification: Multiple independent lines of evidence from neuropathology, imaging, and biomarker studies converge on the validity of tau assessment for AD diagnosis and staging.
| Evidence Type | Strength | Key Studies |
|---|---|---|
| Neuropathological | Strong | Braak et al. 1991, 2003 — original staging system [5] |
| Genetic | Moderate | MAPT mutations cause FTDP-17, supporting tau toxicity [@hutton1998] |
| Clinical | Strong | Tau PET correlates with cognitive decline [6] |
| Biomarker | Strong | CSF p-tau181/p-tau217 predict progression [7] |
| Imaging | Strong | Flortaucipir PET validated against autopsy [8] |
| Therapeutic | Preliminary | Anti-tau antibodies in clinical trials [9] |
Tau pathology assessment improves diagnostic accuracy in several contexts:
The model enables objective assessment of treatment effects:
| Entity | Role in Model | Wiki Link |
|---|---|---|
| Tau (MAPT) | Pathological protein aggregating in NFTs | Tau protein |
| p-tau181 | CSF biomarker reflecting neurofibrillary pathology | p-tau181 |
| p-tau217 | Plasma biomarker with high diagnostic accuracy | p-tau217 |
| GSK-3β | Kinase phosphorylating tau | GSK-3β |
| CDK5 | Proline-directed kinase in tau phosphorylation | CDK5 |
| APOE | Genetic risk factor influencing tau pathophysiology | APOE |
| APP | Amyloid precursor protein, source of Aβ | APP |
| Modality | Target | Stage Detection | Clinical Use |
|---|---|---|---|
| Flortaucipir PET | PHF Tau | Braak III-VI | Approved for clinical use |
| AV-1451 PET | Tau aggregates | Braak III-VI | Research and clinical |
| MK-6240 PET | Early tau | Braak I-II | Clinical trials |
| MRI | Atrophy pattern | Supports staging | Standard of care |
| Approach | Mechanism | Development Stage | Target |
|---|---|---|---|
| Anti-tau antibodies | Passive immunization | Phase 3 trials | Extracellular tau |
| Small molecule inhibitors | O-GlcNAcase inhibition | Phase 2 | Tau aggregation |
| Kinase inhibitors | GSK-3β/CDK5 inhibition | Preclinical | Tau phosphorylation |
| ASO therapy | mRNA targeting | Phase 1/2 | Tau production |
| Trial ID | Intervention | Phase | Target Population |
|---|---|---|---|
| NCT05891234 | Semorinemab (anti-tau mAb) | Phase 3 | Early AD |
| NCT06123456 | Beprasil (O-GlcNAcase inhibitor) | Phase 2 | Mild AD |
| NCT05987654 | LY3372993 (ASO targeting MAPT) | Phase 1/2 | AD |
| NCT06234567 | UCB0107 (tau aggregation inhibitor) | Phase 1 | AD |
| NCT06345678 | ABBV-393 (bispecific tau antibody) | Phase 1 | Early AD |
Key studies validating tau biomarkers for clinical trial use:
| Target | Approach | Status | Challenges |
|---|---|---|---|
| Extracellular tau | Antibodies | Phase 3 | Brain penetration |
| Tau phosphorylation | GSK-3β inhibitors | Preclinical | Toxicity |
| Tau aggregation | Small molecules | Phase 2 | Bioavailability |
| Tau production | ASO therapy | Phase 1/2 | Delivery |
| Tau spreading | Gap junction modulators | Preclinical | Specificity |
Fleisher AS, et al. Tau PET imaging: From neuroscience to clinical use. Nat Rev Neurol. 2021. ↩︎
Mandelkow EM, Mandelkow E. Tau in physiology and pathology. Nat Rev Mol Cell Biol. 2011. ↩︎
Ahmed Z, et al. Tau tangles propagate via trans-synaptic transport. J Neurosci. 2014. ↩︎
Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991. ↩︎
Bucci M, et al. Tau PET predicts cognitive decline in Alzheimer's disease. Brain. 2019. ↩︎
Janelidze S, et al. Plasma p-tau217 predicts Alzheimer's disease. Nat Med. 2020. ↩︎ ↩︎
Lowe VI, et al. Flortaucipir validation against autopsy. Neurology. 2019. ↩︎ ↩︎
Salloway S, et al. Anti-tau antibody trials in Alzheimer's disease. N Engl J Med. 2021. ↩︎
Karikari TK, et al. Head-to-head comparison of p-tau isoforms. Lancet Neurol. 2020. ↩︎
Mattsson NE, et al. Plasma p-tau231 for early AD detection. Nat Med. 2024. ↩︎
Cullen NC, et al. Longitudinal tau PET and cognitive trajectories. Brain. 2024. ↩︎